Show simple item record

dc.creatorCordero García, Eugenia
dc.creatorBaéz Astúa, Andrés
dc.creatorRoa Martínez, Yolanda
dc.creatorRamírez Mayorga, Vanessa
dc.creatorAlpízar Alpízar, Warner
dc.date.accessioned2019-10-18T20:24:56Z
dc.date.available2019-10-18T20:24:56Z
dc.date.issued2019-09-19
dc.identifier.citationhttps://doi.org/10.3332/ecancer.2019.962es_ES
dc.identifier.urihttp://hdl.handle.net/10669/79581
dc.description.abstractJustification: The prevalence of gastric cancer (GC) with increased expression of the HER2 oncoprotein shows important variations worldwide. Incidence and mortality rates of GC in Costa Rica are among the highest in Latin America and the world; however, the prevalence of HER2-positive cases in this country is unknown. Evaluation of this parameter is important to decide the therapeutic approach for GC patients. The aim of this study was to provide an estimation of the prevalence of GC patients overexpressing the HER2 oncogene in Costa Rica. Methods: The investigation was carried out in two phases. The first one consisted of a retrospective review of 331 clinical records of patients diagnosed with advanced or metastatic GC from January 2010 to January 2012 in four hospitals in Costa Rica. In the second phase, immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) analyses were performed in formalin-fixed and paraffin-embedded (FFPE) surgical samples from 50 patients diagnosed with GC between 2012 and 2015. Results: Of the 331 clinical files reviewed, the assessment of HER2 status was carried out in 62 patients (18.7%), of which only five (8%) were HER2-positive. In the 50 surgical specimens in which IHC and FISH analyses were performed, two of them (4%) presented overexpression and amplification of the HER2 oncogene. Conclusion: This study suggests that the prevalence of GC cases overexpressing the HER2 oncogene in Costa Rica is less than 8%. This is the first attempt ever undertaken to estimate the prevalence of HER2-positivity in GC in Costa Rica.es_ES
dc.language.isoen_USes_ES
dc.sourceecancer 2019, 13:962es_ES
dc.subjectoncogenees_ES
dc.subjectgastric canceres_ES
dc.subjectcanceres_ES
dc.subjectimmunohistochemistryes_ES
dc.subjectfluorescent in situ hybridisationes_ES
dc.titleEvaluation of the expression of the oncogene C-ERBB-2/HER2 in gastric cancer cases from Costa Ricaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.3332/ecancer.2019.962
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones en Salud (INISA)es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record